Skip to main content
BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%
Prezzi
Inizia→
stocksJul 21, 2026, 5:06 AM

Novartis Q2 2026 Earnings Beat on Revenue and EPS, Reaffirms Guidance

Novartis reported Q2 2026 net sales of $14.41B (est. $13.94B) and core EPS of $2.41 (est. $2.16). The company reaffirmed its full-year 2026 guidance.

NVS

Novartis reported second-quarter 2026 earnings that exceeded analyst expectations. Net sales came in at $14.41 billion versus the $13.94 billion consensus estimate. Core earnings per share were $2.41, topping the $2.16 forecast.

Key product sales results (vs. estimates):

  • Promacta/Revolade: $179M (est. $202.1M)
  • Tasigna: $142M (est. $147.2M)
  • Kisqali: $1.70B (est. $1.68B)
  • Pluvicto: $651M (est. $671.7M)
  • Entresto: $1.18B (est. $1.29B)
  • Cosentyx: $1.82B (est. $1.14B)

Cosentyx significantly outperformed expectations, while Entresto and Pluvicto fell short. The company reaffirmed its full-year 2026 guidance. Novartis shares are likely to react positively given the headline beats.

Source: First Squawk